Previous 10 | Next 10 |
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases today announced th...
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced ...
Aerie Pharmaceuticals, Inc. (AERI) Q2 2021 Earnings Conference Call August 4, 2021 5:00 PM ET Company Participants Ami Bavishi – Director of Investor Relations Vince Anido – Chairman and Chief Executive Officer Tom Mitro – President and Chief Operating Officer Chris State...
Image source: The Motley Fool. Aerie Pharmaceuticals, inc (NASDAQ: AERI) Q2 2021 Earnings Call Aug 4, 2021 , 5:00 p.m. ET Operator Continue reading For further details see: Aerie Pharmaceuticals, inc (AERI) Q2 2021 Earnings Call Transcrip...
Aerie Pharmaceuticals (NASDAQ:AERI): Q2 Non-GAAP EPS of -$0.83 misses by $0.18; GAAP EPS of -$0.84 misses by $0.02. Revenue of $27.2M (+50.9% Y/Y) beats by $0.9M. Press Release For further details see: Aerie Pharmaceuticals EPS misses by $0.18, beats on revenue
Second Quarter 2021 Net Revenues of $27.2 Million Increased 50.8% over Second Quarter 2020 Second Quarter 2021 Net Revenue Per Bottle of $89, up 14.7% over Second Quarter 2020 Phase 2b Topline Results for AR-15512 (COMET-1) Expected in the Third Quarter of 2021 ...
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, announced today ...
Aerie Pharmaceuticals (AERI) is approaching a support level. If this support level is broken, a breakdown is expected. Aerie Pharmaceuticals, Inc. ( AERI ) engages in the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, re...
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced ...
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases today announced th...
News, Short Squeeze, Breakout and More Instantly...
Aerie Pharmaceuticals Inc. Company Name:
AERI Stock Symbol:
NASDAQ Market:
Aerie Pharmaceuticals Inc. Website:
Leveraging Alcon’s robust commercial capabilities and resources to drive further growth and access to Rocklatan and Rhopressa Acquisition adds pharmaceutical research and development capabilities and further expertise for future product pipeline Expands Al...
Third Quarter Glaucoma Franchise Net Revenues of $36.1 Million, up 23% over Third Quarter 2021 Previously Announced Agreement to be Acquired by Alcon; Transaction Expected to Close in the Fourth Quarter of 2022 Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceut...
NEW YORK, NY / ACCESSWIRE / October 30, 2022 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Altra Industrial Motion Corp. (NA...